Sanofi’s portfolio of medicines includes the first biologic treatment approved for people six to twelve years with severe atopic dermatitis (the most common form of eczema). This medicine is also approved for people 12 years and older with moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and for adults with moderate-to-severe chronic rhinosinusitis with nasal polyps. Sanofi is also studying it in a variety of other type 2 inflammatory diseases, including eosinophilic esophagitis, chronic obstructive pulmonary disease, and more than a half dozen others.
The second medicine in Sanofi’s immunology portfolio is for adults with moderate-to-severe rheumatoid arthritis. It is also being studied as a potential treatment for polyarticular juvenile idiopathic arthritis and systemic juvenile arthritis.
In addition to Sanofi’s deep commitment and investment in treating diseases driven by type 2 inflammation, it continues to actively expand its work across other immunological pathways that contribute to a variety of diseases, leveraging new approaches and platform technologies for the benefit of patients.
Inspired by patients worldwide
atopic dermatitis (US)
atopic dermatitis (Japan)
Research & Development
Building on its leadership in type 2 inflammation, Sanofi is advancing a robust pipeline against a range of immunological and inflammatory disorders.
The Next Breath
The Next Breath is for everyone with a role to play in building a brighter future for people living with severe asthma.
Change AD’s mission is to empower and support patients around the world by changing the way people think about atopic dermatitis.